So, I do think that be it the largecap generic-focused companies like Sun, Dr Reddy’s, Cipla, or some of the API-based companies whether it is Laurus Labs, Neuland Labs, Glenmark, these companies are sounding far more confident about their growth, both in the US market in terms of their speciality products or domestic market.
